Intron retention in STAT2 relates to lung cancer immunotherapy response
Intron retention in the STAT2 gene regulates immune signaling and correlates with patient survival after PD-L1 immunotherapy.
Intron retention in the STAT2 gene regulates immune signaling and interferon responses. This process correlates with patient survival after anti-programmed death-ligand 1 (PD-L1) immunotherapy.
Researchers used long-read RNA sequencing to map alternative RNA splicing in human primary lung adenocarcinomas. Alternative RNA splicing is a way to create different messenger RNA (mRNA) isoforms.
The study identified more than 149,000 full-length mRNA isoforms. More than half of these were unannotated.
Many isoforms occurred in immune-related genes. These were particularly within the type I interferon response pathway.
Retained introns in the STAT2 gene produced altered protein isoforms. These findings position alternative splicing as a regulator of tumor immune responses.
Key facts
- More than 149,000 full-length mRNA isoforms were identified.
- Intron retention in STAT2 correlates with patient survival after PD-L1 immunotherapy.
- Over half of the identified mRNA isoforms were unannotated.